A Phase I Clinical Study of HS-10502 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the
safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 in subjects with
homologous recombination repair (HRR) gene mutant or homologous recombination deficiency
(HRD) positive advanced solid tumors.